Although the structural modification of Gal-2 using protein engineering or formulation design for suitable drug delivery might be necessary to prevent side effects such as ischemia risk for coronary artery disease patients [36,37], Gal-2 can be used as a substitute to conventional antibiotics. The gene discussed is LGALS2; the disease is ischemia.